A prospective, open label study to investigated the safety and steady state pharmacokinetics of Cortexolone 17a-propionate (CB-03-01; 1 % cream) in patients with with moderate to severe acne vulgaris.
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2015
At a glance
- Drugs CB 03 01 (Primary)
- Indications Acne vulgaris
- Focus Adverse reactions; Pharmacodynamics
- 10 Dec 2015 New trial record